Nevertheless, targeting therapy on KRAS oncogene mutation seems unrealistic, so some alternative treatments targeting its downstream pathways (especially on breaking PTSs and restoring the proteostasis of acinar cells, such as modulating HSF1) need to be used to prevent the initiation of PDAC and improve prognosis of pancreatic cancer patients. Here, KRAS is linked to familial pancreatic carcinoma.